GOED News Alerts: Analysis on events affecting EPA and DHA Markets

EFSA Publishes Long-Chain PUFA Upper Limit Opinion

July 27: In a much-anticipated decision, the European Food Safety Authority (EFSA) this week published a Scientific Opinion on the tolerable upper intake level (UL) for EPA, DHA and DPA omega-3s. The Opinion stated that available data are insufficient to establish a UL for the n-3 LCPUFA (individually or combined) for any population group. The Panel noted, “at observed intake levels, consumption of n-3 LCPUFA has not been associated with adverse affects in healthy children or adults.” The Panel did specify that there was no significant risk with long-term supplemental intakes of EPA and DHA combined up to about 5g/day; it also qualified that supplemental intakes up to 1.8g/day of EPA alone do not raise safety concerns for the adult population and up to 1g/day for DHA alone does not raise any safety concerns for the general population.
The decision, which was published in the EFSA Journal, was the result of a request from the European Commission (EC) to deliver a scientific opinion on the Tolerable Upper Intake Level of the n-3 LCPUFAs EPA, DHA and DPA.
In January 2011, Germany asked the EC to start a regulatory procedure to set an upper limit intake for EPA and DHA in the European Union. At that time, Germany recommended a limit of 1.5g per day from all food sources. In June 2011 the EC requested EFSA “review the existing scientific data on the possible link between the intake of omega-3 long chain polyunsaturated fatty acids, alone or combined (DHA and/or EPA and/or DPA) and adverse health effects, and to advise the Commission on a tolerable upper level of intake (UL) for omega-3 long-chain polyunsaturated fatty acids, alone or combined (DHA and/or EPA and/or DPA) for the general population and, if appropriate, for vulnerable subgroups of the population.” Concerns raised by Germany and possibly other Member States resulted in three Article 13 claims being put on hold due to intake levels > 2g/day. (See GOED's January 28, 2011, March 28, 2011 and September 16, 2011 News Alerts).
GOED, in an effort to aid EFSA in their review, commissioned both a comprehensive hazard characterization and intake assessment. Both were submitted to EFSA earlier this year (See GOED's February 17, 2012 and March 5 2012 News Alerts).
GOED’s intake assessment included a complete evaluation of long-chain omega-3 intakes in the EU, with specific examination of background, current and potential future intakes. The final report supports the existence of low long-chain omega-3 intake from background diets and shows that the addition of supplements and fortified foods, while increasing intakes, would likely result in a maximum mean intake of 1g/day and not be greater than 2g/day for very high consumers.
In the safety assessment, which measured hazard characterization evidence of EPA, DHA and DPA, the conclusion was that no appropriate studies could be identified to define specific intake levels or intake/ response relationships that could be used to define a UL for the effects. These conclusions mirror those reached by the Norwegian Scientific Committee for Food Safety (VKM) last year (see GOED’s June 29, 2011 News Alert).
This week’s EFSA opinion concurs, stating that available data are insufficient to establish a UL for the n-3 LCPUFA (individually or combined) for any population group. The report states, “Long-term supplemental intakes of EPA and DHA combined up to about 5g/day do not appear to increase the risk of spontaneous bleeding episodes or bleeding complications or affect glucose homeostasis immune function or lipid peroxidation, provided the oxidative stability of the n-3 LCPUFA is guaranteed.”

As mentioned above, for EPA alone, the Panel stated supplemental intakes up to 1.8g/day do not raise safety concerns for the adult population. For DHA alone, the Panel said that up to 1g/day does not raise any safety concerns for the general population. GOED believes that the low 1g/day number is a result of what the Panel is quoting as “limited” data being available on the effects of long-term supplementation with DHA alone at higher doses. There is no reason to believe that the safety of DHA alone, and for that matter EPA alone, is any different than the safety of EPA + DHA. No dietary recommendations were made for DPA.
Finally, the report commented that limited data are available on the effects of long-term supplementation with omega-3s at higher doses. The Panel also noted that observed intakes of EPA and DHA from food and supplements in European populations are generally below these amounts. Finally, it is worth noting that the EFSA recommendation of 5g/day is significantly higher than the current 3g/day upper limit in the U.S.
Looking Ahead:
As mentioned above, certain omega-3 claims were put on hold as a result of this pending upper limit decision. Now that the decision has been published, if necessary, GOED will continue to be proactive on moving those claims forward.
In addition, in June 2011, the Swiss government in SR 817.022.104 (Regulation on Special Food). Annex 13 adopted an upper limit of 250 mg of EPA and DHA intake for the general population and up to 400 mg EPA and DHA for pregnant and lactating women. GOED will approach the government with the EFSA opinion to ask them to reconsider their position.


GOED Pavillion at HiEurope

GOED is organizing an omega-3 pavillion at this fall's Health Ingredients Europe show, which takes place in Frankfurt, Germany on November 13-15. If you are interested in learning more about how to participate in this pavillion, please contact membership engagement director Mike Roberts.

Membership Update

July 2 — GOED welcomes three new companies to its membership, Nisshin Pharma, Omega 3 Galil Ltd. and Shandong Yuwang Pharmaceutical Co. Ltd.

Nisshin Pharma, which joined at the Base Level, has focused on production and marketing of health care products. The primary contact is Satoshi Kiyohara, who can be reached at kiyoharas@mail.ni-net.co.jp.

Also joining at the Base Level is Israeli-based Omega 3 Galil, a manufacturer of omega-3 supplements primarily for children and pregnant women. The primary contact is Guy Ben Zvi, who can be reached at guy@omega3galil.com.

Shandong Yuwang Pharmaceutical Co. is a Chinese manufacturer of refined fish oil and soft gels that joins GOED as a base level member. The primary contact is Liu Xiqian, who can be reached at liuxiqian@yuwangcn.com.

Special Offers Available to Members

If you haven't done so recently, check out the Special Offers section of the GOED website (you must first complete a free registration to the Member Section). This area is updated regularly and includes special GOED member discounts for items like upcoming conferences, industry reports and liability insurance.
Twitter Account not yet Authorized
Follow us on Twitter
GOED Exchange tidbit
Heard at the GOED Exchange...."The average intake of long-chain omega-3s in China is too low at 37.6 mg/day, making it one of the lowest globally..."

Be part of the conversation. Join our LinkedIn group today.
Copyright © 2012 Global Organization for EPA and DHA Omega-3s, All rights reserved.